Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status

Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin when used at the time of interval cytoreductive surgery (ICS) after neoadjuvant chemotherapy (NACT) has been shown to provide a survival advantage compared to interval cytoreduction alone for patients with advanced epithelial ovarian c...

Descripción completa

Detalles Bibliográficos
Autores principales: Penn, Courtney A., Carballo, Erica V., Walsh, Christine S., Zivanovic, Oliver, Kim, Kenneth H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149186/
https://www.ncbi.nlm.nih.gov/pubmed/35652061
http://dx.doi.org/10.1016/j.gore.2022.101009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149186/
https://www.ncbi.nlm.nih.gov/pubmed/35652061
http://dx.doi.org/10.1016/j.gore.2022.101009

Ejemplares similares